Savara
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.About SVRA
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis.
SVRA Key Statistics
Stock Snapshot
Savara(SVRA) stock is priced at $6.45, giving the company a market capitalization of 1.31B. It carries a P/E multiple of -12.05.
During the trading session on 2025-12-27, Savara(SVRA) shares reached a daily high of $6.50 and a low of $6.25. At a current price of $6.45, the stock is +3.2% higher than the low and still -0.8% under the high.
Trading volume for Savara(SVRA) stock has reached 949.06K, versus its average volume of 4.3M.
The stock's 52-week range extends from a low of $1.89 to a high of $7.01.
The stock's 52-week range extends from a low of $1.89 to a high of $7.01.
SVRA News
Savara (SVRA) just took a key regulatory step by resubmitting its Biologics License Application for MOLBREEVI and asking the FDA for Priority Review, a move tha...
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Savara, with a price target of $10.00. Claim 70% Off TipRanks This Holid...
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Savara (SVRA) to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted...
Analyst ratings
100%
of 8 ratingsMore SVRA News
In December 2025, Savara Inc. was added to the S&P Biotechnology Select Industry Index after the European Patent Office signaled its intention to grant patent p...
Savara, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on...